Vertex Pharmaceuticals’ CRISPR-based therapy made history as the first drug of its type, transforming care options for sickle ...

Scientists announced the Biodiversity Cell Atlas project to map every cell type across all eukaryotic life on Earth.

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...

Associate Professor Yusuke Imoto at Kyoto University has developed iRECODE, a comprehensive computational method that removes noise from single-cell data, revealing the true activity of individual ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...

Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...

In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de ...